Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;18(9):e70004.
doi: 10.1111/irv.70004.

Prevalence of SARS-CoV-2 Antibodies in Kosovo-Wide Population-Based Seroepidemiological Study

Affiliations

Prevalence of SARS-CoV-2 Antibodies in Kosovo-Wide Population-Based Seroepidemiological Study

Naser Ramadani et al. Influenza Other Respir Viruses. 2024 Sep.

Abstract

Background: Seroprevalence studies have proven to be an important tool in tracking the progression of the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to measure the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the general population of Kosovo by gender, age group and region and among asymptomatic people.

Method: The Institute of Public Health of Kosovo conducted a cross-sectional population-based survey, aligned with the protocols of the WHO Unity Studies, from the beginning of May to the end of June 2021.

Results: The survey covered a total of 2204 people with a response rate of 91.8% (41.9% [923] males and 51.2% [1281] females). In May to June 2021, the prevalence of antibodies in the overall population (IgG antibodies ≥ 1.1) was 37.0%. Seroprevalence was 34.4% in men and 38.9% in women (p < 0.05), with the highest percentage (48.7%) found in the 60-69 years' age group. The overall prevalence of acute IgM antibodies (IgM ≥ 1.1) was 1% (95% CI: 0.7%-1.5%), with no significant difference between genders and the highest prevalence among participants of 60-69 years of age (1.6%; 95% CI: 0.7%-3.6%).

Conclusion: A high prevalence of antibodies against SARS-CoV-2 was found in Kosovo before the start of the vaccination campaign. However, the results of the survey suggested that, by the end of June 2021, a desirable level of protection from the SARS-CoV-2 virus had not been reached.

Keywords: COVID‐19; Kosovo; SARS‐CoV‐2; antibodies; seroepidemiological study; seroprevalence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Geographical distribution of SARS‐CoV‐2 seroprevalence in Kosovo, May–June 2021. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities or concerning the delimitation of its frontiers or boundaries. All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council Resolution 1244 (1999).

References

    1. Huang C., Wang Y., Li X., et al., “Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China,” Lancet 395, no. 10223 (2020): 497–506, 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. Zhu N., Zhang D., Wang W., et al., “A Novel Coronavirus From Patients With Pneumonia in China, 2019,” New England Journal of Medicine 382 (2020): 727–733, 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. “WHO Statement on Novel Coronavirus in Thailand,” in News release, World Health Organization [Website], January 13, 2020 (Geneva: World Health Organization, 2023), accessed October 18, 2023, https://www.who.int/news/item/13‐01‐2020‐who‐statement‐on‐novel‐coronavi....
    1. “WHO Director‐General's Opening Remarks at the Media Briefing on COVID‐19 ,” World Health Organization [Website], March 11, 2020 (Geneva: World Health Organization, 2023), accessed October 18, 2023, https://www.who.int/director‐general/speeches/detail/who‐director‐genera....
    1. “WHO Coronavirus Disease (COVID‐19) Dashboard [Database]” (Geneva: World Health Organization, 2023), accessed October 18, 2023, https://covid19.who.int/.

Grants and funding

LinkOut - more resources